PRPO – Precipio Inc

PRPO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.5

Margin Of Safety %

-19

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

22.02

Target Price

Analyst Recom

Performance Q

-7.41

Upside

-137.6%

Beta

1.42

Ticker: PRPO

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-16	PRPO	21.78	N/A	N/A	0
2026-10-19	PRPO	21.9	N/A	N/A	0
2026-10-20	PRPO	21.82	N/A	N/A	0
2026-10-21	PRPO	21.13	N/A	N/A	0
2026-10-22	PRPO	20.75	N/A	N/A	0
2026-10-23	PRPO	20.49	N/A	N/A	0
2026-10-26	PRPO	19.5	N/A	N/A	0
2026-10-27	PRPO	19.43	N/A	N/A	0
2026-10-28	PRPO	18.86	N/A	N/A	0
2026-10-29	PRPO	19.12	N/A	N/A	0
2026-10-30	PRPO	18.09	N/A	N/A	0
2026-11-02	PRPO	17.99	N/A	N/A	0
2026-11-03	PRPO	19.17	N/A	N/A	0
2026-11-04	PRPO	19.86	N/A	N/A	0
2026-11-05	PRPO	18.83	N/A	N/A	0
2026-11-06	PRPO	18.94	N/A	N/A	0
2026-11-09	PRPO	22.18	N/A	N/A	0
2026-11-10	PRPO	23.56	N/A	N/A	0
2026-11-11	PRPO	24.58	N/A	N/A	0
2026-11-12	PRPO	23.08	N/A	N/A	0
2026-11-13	PRPO	21.63	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-16	PRPO	21.72	-	-	-6.25
2026-10-19	PRPO	21.93	-	-	-6.25
2026-10-20	PRPO	21.93	-	-	-6.25
2026-10-21	PRPO	21.83	-	-	-6.25
2026-10-22	PRPO	20.75	-	-	-6.25
2026-10-23	PRPO	20.12	-	-	-6.25
2026-10-26	PRPO	19.58	-	-	-6.25
2026-10-27	PRPO	19.06	-	-	-6.25
2026-10-28	PRPO	18.68	-	-	-6.25
2026-10-29	PRPO	19.47	-	-	-6.25
2026-10-30	PRPO	18.22	-	-	-6.25
2026-11-02	PRPO	17.79	-	-	-6.25
2026-11-03	PRPO	18.83	-	-	-6.25
2026-11-04	PRPO	19.58	-	-	-6.25
2026-11-05	PRPO	19.00	-	-	-6.25
2026-11-06	PRPO	18.66	-	-	-6.25
2026-11-09	PRPO	22.17	-	-	-6.25
2026-11-10	PRPO	23.54	-	-	-6.25
2026-11-11	PRPO	24.58	-	-	-6.25
2026-11-12	PRPO	23.51	-	-	-6.25
2026-11-13	PRPO	22.02	-	-	-6.25
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-16	PRPO	-1.76	0.93	4.37
2026-10-19	PRPO	-1.76	0.93	4.37
2026-10-20	PRPO	-1.76	0.93	4.37
2026-10-21	PRPO	-1.76	0.93	4.37
2026-10-22	PRPO	-1.76	0.93	4.37
2026-10-23	PRPO	-1.76	0.93	4.37
2026-10-26	PRPO	-1.76	0.93	4.37
2026-10-27	PRPO	-1.76	0.93	3.75
2026-10-28	PRPO	-1.76	0.93	3.75
2026-10-29	PRPO	-1.76	0.93	3.75
2026-10-30	PRPO	-1.76	0.93	3.75
2026-11-02	PRPO	-1.76	0.93	3.75
2026-11-03	PRPO	-1.76	0.93	3.75
2026-11-05	PRPO	-1.76	0.93	3.75
2026-11-06	PRPO	-1.76	0.93	3.75
2026-11-09	PRPO	-1.76	0.96	3.75
2026-11-10	PRPO	-1.76	0.96	3.75
2026-11-11	PRPO	-1.76	0.96	3.50
2026-11-12	PRPO	-1.76	0.96	3.50
2026-11-13	PRPO	-1.76	0.96	3.50
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.93

Avg. EPS Est. Next Quarter

Insider Transactions

-1.76

Institutional Transactions

0.96

Beta

1.42

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

17.84

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

55.1

Max Drawdown 5-Year %

-90.4

Target Price

P/E

Forward P/E

PEG

P/S

1.43

P/B

2.67

P/Free Cash Flow

28.55

EPS

-0.64

Average EPS Est. Cur. Y

-6.25

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-4.12

Relative Volume

0.15

Return on Equity vs Sector %

-34.1

Return on Equity vs Industry %

-19.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ PRPO Healthcare

$22.13

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

10/20

Pullback

13/25

Volume

11/15

Valuation

6/20

TP/AR

2/10

Options

0/10

RSI

52.5

Range 1M

55.4%

Sup Dist

0.6%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

11/30

Estimates

3/20

Inst/Vol

4/15

Options

0/10

EPS Yr

EPS NY

52W%

26.4%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -17.3% upside

Quality

5/30

Valuation

0/30

Growth

4/25

Stability

6/10

LT Trend

5/5

Upside

-17.3%

Quality

MoS

-19%

PRPO — P/E HistoricalDiagnostics & Research

Precipio, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 61

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

PRPO

Latest News

—

Caricamento notizie per PRPO…

stock quote shares PRPO – Precipio Inc Stock Price stock today

news today PRPO – Precipio Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRPO – Precipio Inc yahoo finance google finance

stock history PRPO – Precipio Inc invest stock market

stock prices PRPO premarket after hours

ticker PRPO fair value insiders trading

PRPH – ProPhase Labs Inc

PRPH — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.54

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.01

Target Price

160

Analyst Recom

Performance Q

-93.37

Upside

N/A

Beta

-0.54

Ticker: PRPH

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-16	PRPH	0.0091	N/A	N/A	0
2026-10-19	PRPH	0.0085	N/A	N/A	0
2026-10-20	PRPH	0.0095	N/A	N/A	0
2026-10-21	PRPH	0.009	N/A	N/A	0
2026-10-22	PRPH	0.0095	N/A	N/A	0
2026-10-23	PRPH	0.0092	N/A	N/A	0
2026-10-26	PRPH	0.0092	N/A	N/A	0
2026-10-27	PRPH	0.0086	N/A	N/A	0
2026-10-28	PRPH	0.0085	N/A	N/A	0
2026-10-29	PRPH	0.008	N/A	N/A	0
2026-10-30	PRPH	0.0077	N/A	N/A	0
2026-11-02	PRPH	0.0071	N/A	N/A	0
2026-11-03	PRPH	0.0059	N/A	N/A	0
2026-11-04	PRPH	0.0062	N/A	N/A	0
2026-11-05	PRPH	0.0054	N/A	N/A	0
2026-11-06	PRPH	0.0052	N/A	N/A	0
2026-11-09	PRPH	0.0055	N/A	N/A	0
2026-11-10	PRPH	0.0055	N/A	N/A	0
2026-11-11	PRPH	0.005	N/A	N/A	0
2026-11-12	PRPH	0.0046	N/A	N/A	0
2026-11-13	PRPH	0.0049	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

-0.54

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

34.8

Max Drawdown 5-Year %

Target Price

160

P/E

Forward P/E

PEG

P/S

P/B

0.22

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

-1.55

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

695.7

Return on Equity vs Industry %

710.5

EPS 1 7Days Diff

EPS 1 30Days Diff

-1.18

EBIT Estimation

No data found for PRPH

PRPH — P/E HistoricalDrug Manufacturers - Specialty & Generic

ProPhase Labs, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 19

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides Nebula focuses on genomics testing technologies a comprehensive method for analyzing entire genomes, including the genes and chromosomes in deoxyribonucleic acid (DNA). It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Uniondale, New York.

PRPH

Latest News

—

Caricamento notizie per PRPH…

stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today

news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance

stock history PRPH – ProPhase Labs Inc invest stock market

stock prices PRPH premarket after hours

ticker PRPH fair value insiders trading

NEO – Neogenomics Inc.

NEO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.35

Margin Of Safety %

Put/Call OI Ratio

0.1

EPS Next Q Diff

0.04

EPS Last/This Y

0.08

EPS This/Next Y

0.11

Price

16.01

Target Price

23.4

Analyst Recom

1.36

Performance Q

-0.87

Upside

-154.6%

Beta

1.84

Ticker: NEO

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-16	NEO	16.66	0.08	0.04	16907
2026-10-19	NEO	16.44	0.08	0.06	16536
2026-10-20	NEO	16.61	0.08	0.10	16552
2026-10-21	NEO	17.03	0.08	0.31	16567
2026-10-22	NEO	16.38	0.08	0.00	16601
2026-10-23	NEO	16.59	0.08	0.03	16584
2026-10-26	NEO	16.69	0.08	0.00	16583
2026-10-27	NEO	17.27	0.08	0.59	16677
2026-10-28	NEO	17.99	0.09	0.11	16682
2026-10-29	NEO	17.92	0.09	2.67	16693
2026-10-30	NEO	17.38	0.08	0.67	16677
2026-11-02	NEO	16.45	0.08	0.64	16681
2026-11-03	NEO	16.84	0.08	1.15	16670
2026-11-04	NEO	17.14	0.09	0.35	16700
2026-11-05	NEO	16.5	0.09	0.88	16704
2026-11-06	NEO	16.84	0.09	0.02	16708
2026-11-09	NEO	17.59	0.09	0.25	16718
2026-11-10	NEO	16.97	0.09	0.00	16729
2026-11-11	NEO	16.83	0.09	0.76	16733
2026-11-12	NEO	16.55	0.10	0.03	16928
2026-11-13	NEO	15.94	0.10	0.27	16899
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-16	NEO	16.66	84.8	-	0.19
2026-10-19	NEO	16.43	84.8	-	0.19
2026-10-20	NEO	16.43	84.8	-	0.19
2026-10-21	NEO	16.61	84.8	-	0.19
2026-10-22	NEO	16.39	84.8	-	0.19
2026-10-23	NEO	16.58	84.8	-	0.19
2026-10-26	NEO	16.69	84.8	-	0.19
2026-10-27	NEO	17.27	84.8	-	0.19
2026-10-28	NEO	18.00	84.8	-	0.19
2026-10-29	NEO	17.91	84.8	-	0.19
2026-10-30	NEO	17.37	84.8	-	0.19
2026-11-02	NEO	16.49	11.1	-	0.20
2026-11-03	NEO	16.84	12.1	-	0.20
2026-11-04	NEO	17.14	7.6	-	0.20
2026-11-05	NEO	16.50	7.6	-	0.20
2026-11-06	NEO	16.84	7.6	-	0.20
2026-11-09	NEO	17.59	7.6	-	0.20
2026-11-10	NEO	16.97	7.6	-	0.20
2026-11-11	NEO	16.83	7.6	-	0.20
2026-11-12	NEO	16.55	7.6	-	0.20
2026-11-13	NEO	16.01	7.6	-	0.20
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-16	NEO	-1.22	10.47	11.23
2026-10-19	NEO	-1.22	10.48	11.23
2026-10-20	NEO	-1.22	10.48	11.23
2026-10-21	NEO	-1.22	10.48	11.23
2026-10-22	NEO	-1.22	10.48	11.23
2026-10-23	NEO	-1.22	10.48	11.23
2026-10-26	NEO	-1.22	10.47	11.23
2026-10-27	NEO	-1.22	10.47	11.28
2026-10-28	NEO	-1.22	10.47	11.28
2026-10-29	NEO	-1.22	10.47	11.28
2026-10-30	NEO	-1.22	10.47	11.28
2026-11-02	NEO	-1.21	10.76	11.20
2026-11-03	NEO	-1.21	10.76	11.20
2026-11-05	NEO	-1.21	10.76	11.20
2026-11-06	NEO	-1.21	10.76	11.20
2026-11-09	NEO	-1.21	10.55	11.20
2026-11-10	NEO	-1.21	10.55	11.20
2026-11-11	NEO	-1.21	10.55	10.35
2026-11-12	NEO	-1.21	10.55	10.35
2026-11-13	NEO	-1.21	10.55	10.35
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.01

Avg. EPS Est. Current Quarter

0.06

Avg. EPS Est. Next Quarter

0.05

Insider Transactions

-1.21

Institutional Transactions

10.55

Beta

1.84

Average Sales Estimate Current Quarter

210

Average Sales Estimate Next Quarter

206

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

62.4

Max Drawdown 5-Year %

-88.5

Target Price

23.4

P/E

Forward P/E

51.18

PEG

1.03

P/S

2.63

P/B

2.58

P/Free Cash Flow

EPS

-0.25

Average EPS Est. Cur. Y

0.2

EPS Next Y. (Est.)

0.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-4.1

Relative Volume

1.14

Return on Equity vs Sector %

-30.4

Return on Equity vs Industry %

-15.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

◆ NEO Healthcare

$16.02

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

12/25

Volume

4/15

Valuation

13/20

TP/AR

4/10

Options

8/10

RSI

41.8

Range 1M

12.3%

🚀

Momentum Growth

Ride accelerating trends

N/A

WATCH

Momentum

8/25

Growth

28/30

Estimates

6/20

Inst/Vol

8/15

Options

8/10

EPS Yr

70%

EPS NY

53.4%

52W%

68.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🔴 SELL -9.9% upside

Quality

5/30

Valuation

2/30

Growth

21/25

Stability

7/10

LT Trend

1/5

Upside

-9.9%

Quality

NEO — P/E HistoricalDiagnostics & Research

NeoGenomics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2500

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO

Latest News

—

Caricamento notizie per NEO…

stock quote shares NEO – Neogenomics Inc. Stock Price stock today

news today NEO – Neogenomics Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NEO – Neogenomics Inc. yahoo finance google finance

stock history NEO – Neogenomics Inc. invest stock market

stock prices NEO premarket after hours

ticker NEO fair value insiders trading

MYGN – Myriad Genetics, Inc.

MYGN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

9.49

Margin Of Safety %

Put/Call OI Ratio

0.21

EPS Next Q Diff

0.02

EPS Last/This Y

-0.79

EPS This/Next Y

0.09

Price

5.64

Target Price

5.81

Analyst Recom

3.11

Performance Q

85.57

Upside

-412.4%

Beta

1.61

Ticker: MYGN

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-16	MYGN	3.97	0.11	0.00	5023
2026-10-19	MYGN	4.22	0.10	0.00	4699
2026-10-20	MYGN	5.55	0.10	0.16	4700
2026-10-21	MYGN	5.55	0.17	0.23	6314
2026-10-22	MYGN	5.72	0.17	0.19	6283
2026-10-23	MYGN	5.84	0.17	0.21	6292
2026-10-26	MYGN	6.03	0.17	0.13	6312
2026-10-27	MYGN	6.28	0.17	0.50	6301
2026-10-28	MYGN	6.64	0.17	0.03	6219
2026-10-29	MYGN	6.66	0.17	0.10	6206
2026-10-30	MYGN	6.33	0.17	1.59	6192
2026-11-02	MYGN	5.82	0.17	0.01	6191
2026-11-03	MYGN	6.03	0.20	0.30	5526
2026-11-04	MYGN	6	0.20	1.37	5545
2026-11-05	MYGN	6.29	0.20	0.50	5606
2026-11-06	MYGN	5.91	0.20	3.89	5574
2026-11-09	MYGN	5.74	0.21	0.04	5632
2026-11-10	MYGN	5.66	0.21	0.06	5645
2026-11-11	MYGN	5.7	0.21	0.08	5660
2026-11-12	MYGN	5.68	0.21	0.09	5660
2026-11-13	MYGN	5.64	0.21	0.19	5668
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-16	MYGN	3.97	0.0	-	-0.74
2026-10-19	MYGN	4.22	0.0	-	-0.74
2026-10-20	MYGN	4.22	0.0	-	-0.74
2026-10-21	MYGN	5.56	0.0	-	-0.74
2026-10-22	MYGN	5.76	0.0	-	-0.74
2026-10-23	MYGN	5.82	0.0	-	-0.74
2026-10-26	MYGN	6.02	0.0	-	-0.74
2026-10-27	MYGN	6.28	0.0	-	-0.74
2026-10-28	MYGN	6.65	0.0	-	-0.74
2026-10-29	MYGN	6.66	0.0	-	-0.74
2026-10-30	MYGN	6.34	0.0	-	-0.74
2026-11-02	MYGN	5.82	0.0	-	-0.74
2026-11-03	MYGN	6.03	0.0	-	-0.74
2026-11-04	MYGN	6.02	0.0	-	-0.74
2026-11-05	MYGN	6.29	0.0	-	-0.74
2026-11-06	MYGN	5.91	0.0	-	-0.74
2026-11-09	MYGN	5.75	-100.0	-	-0.74
2026-11-10	MYGN	5.65	-100.0	-	-0.69
2026-11-11	MYGN	5.70	-100.0	-	-0.69
2026-11-12	MYGN	5.68	-100.0	-	-0.73
2026-11-13	MYGN	5.64	-100.0	-	-0.73
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-16	MYGN	-0.11	-5.02	9.65
2026-10-19	MYGN	-0.11	-4.87	9.65
2026-10-20	MYGN	-0.11	-4.87	9.65
2026-10-21	MYGN	-0.11	-4.87	9.65
2026-10-22	MYGN	-0.11	-4.87	9.65
2026-10-23	MYGN	-0.11	-4.87	9.65
2026-10-26	MYGN	-0.11	-4.45	9.65
2026-10-27	MYGN	-0.11	-4.45	10.46
2026-10-28	MYGN	-0.11	-4.45	10.46
2026-10-29	MYGN	-0.11	-4.45	10.46
2026-10-30	MYGN	-0.11	-4.45	10.46
2026-11-02	MYGN	-0.11	-4.79	10.46
2026-11-03	MYGN	-0.11	-4.79	10.46
2026-11-05	MYGN	-0.11	-4.79	10.46
2026-11-06	MYGN	-0.11	-4.79	10.46
2026-11-09	MYGN	-0.11	-4.92	10.46
2026-11-10	MYGN	-0.11	-4.92	10.46
2026-11-11	MYGN	-0.11	-4.92	9.49
2026-11-12	MYGN	-0.11	-4.92	9.49
2026-11-13	MYGN	-0.11	-4.92	9.49
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.21

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.19

Insider Transactions

-0.11

Institutional Transactions

-4.92

Beta

1.61

Average Sales Estimate Current Quarter

193

Average Sales Estimate Next Quarter

192

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

81.5

Max Drawdown 5-Year %

-90.5

Target Price

5.81

P/E

Forward P/E

PEG

P/S

0.68

P/B

2.01

P/Free Cash Flow

EPS

-1.36

Average EPS Est. Cur. Y

-0.73

EPS Next Y. (Est.)

-0.65

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-16.07

Relative Volume

0.45

Return on Equity vs Sector %

-74.4

Return on Equity vs Industry %

-59.4

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

◆ MYGN Healthcare

$5.66

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

5/20

Pullback

11/25

Volume

11/15

Valuation

5/20

TP/AR

0/10

Options

8/10

RSI

Range 1M

61.4%

Sup Dist

3.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

3/30

Estimates

1/20

Inst/Vol

3/15

Options

8/10

EPS Yr

-1262.8%

EPS NY

1.1%

52W%

55%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +2.7% upside

Quality

6/30

Valuation

4/30

Growth

4/25

Stability

5/10

LT Trend

2/5

Upside

+2.7%

Quality

MYGN — P/E HistoricalDiagnostics & Research

Myriad Genetics, Inc.

Sector: Healthcare

Industry: Diagnostics & Research

Employees: 2700

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile, a genomic profiling test; Prequel Prenatal Screen, a prenatal screening test to screen chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess risk of passing on recessive genetic condition to offspring; SneakPeek Early Gender DNA, a non-invasive blood test that predicts the fetus's gender; FirstGene; and GeneSight Psychotropic Mental Health Medication, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children's Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company has a strategic alliance with SOPHiA GENETICS SA to advance new prostate cancer-specific genomic instability score technology for oncology approaches with AstraZeneca. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

MYGN

Latest News

—

Caricamento notizie per MYGN…

stock quote shares MYGN – Myriad Genetics, Inc. Stock Price stock today

news today MYGN – Myriad Genetics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MYGN – Myriad Genetics, Inc. yahoo finance google finance

stock history MYGN – Myriad Genetics, Inc. invest stock market

stock prices MYGN premarket after hours

ticker MYGN fair value insiders trading

MTD – Mettler-Toledo International, Inc.

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol= #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

stock_superchart: please set a ticker attribute.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

ticker required

Beta

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol= 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol= 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol= 589 450 ]

Please specify a ticker:

NVDA — P/E HistoricalSemiconductors

Sector:

Industry:

Employees:

[News_ _Stock]

stock quote shares MTD – Mettler-Toledo International, Inc. Stock Price stock today

news today MTD – Mettler-Toledo International, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MTD – Mettler-Toledo International, Inc. yahoo finance google finance

stock history MTD – Mettler-Toledo International, Inc. invest stock market

stock prices premarket after hours

ticker fair value insiders trading

GENE – Genetic Technologies Ltd. ADR

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=GENE #%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

GENE — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

0.76

Target Price

6.87

Analyst Recom

Performance Q

-14.99

Upside

N/A

Beta

1.11

Ticker: GENE

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-16	GENE	0.765	N/A	N/A	0
2026-10-19	GENE	0.765	N/A	N/A	0
2026-10-20	GENE	0.765	N/A	N/A	0
2026-10-21	GENE	0.765	N/A	N/A	0
2026-10-22	GENE	0.765	N/A	N/A	0
2026-10-23	GENE	0.765	N/A	N/A	0
2026-10-26	GENE	0.765	N/A	N/A	0
2026-10-27	GENE	0.765	N/A	N/A	0
2026-10-28	GENE	0.765	N/A	N/A	0
2026-10-29	GENE	0.765	N/A	N/A	0
2026-10-30	GENE	0.765	N/A	N/A	0
2026-11-02	GENE	0.765	N/A	N/A	0
2026-11-03	GENE	0.765	N/A	N/A	0
2026-11-04	GENE	0.765	N/A	N/A	0
2026-11-05	GENE	0.765	N/A	N/A	0
2026-11-06	GENE	0.765	N/A	N/A	0
2026-11-09	GENE	0.765	N/A	N/A	0
2026-11-10	GENE	0.765	N/A	N/A	0
2026-11-11	GENE	0.765	N/A	N/A	0
2026-11-12	GENE	0.765	N/A	N/A	0
2026-11-13	GENE	0.765	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=GENE 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

98.5

Max Drawdown 5-Year %

-97.7

Target Price

6.87

P/E

Forward P/E

PEG

P/S

1.24

P/B

2.89

P/Free Cash Flow

EPS

-1.83

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-156.76

Relative Volume

Return on Equity vs Sector %

-680.2

Return on Equity vs Industry %

-667.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=GENE 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=GENE 589 450 ]

No data found for GENE

GENE — P/E HistoricalDiagnostics & Research

[News_GENE _Stock]

stock quote shares GENE – Genetic Technologies Ltd. ADR Stock Price stock today

news today GENE – Genetic Technologies Ltd. ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch GENE – Genetic Technologies Ltd. ADR yahoo finance google finance

stock history GENE – Genetic Technologies Ltd. ADR invest stock market

stock prices GENE premarket after hours

ticker GENE fair value insiders trading

PRPO – Precipio Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PRPO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

PRPH – ProPhase Labs Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PRPH

No data found

No data found

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y